330794-31-5

Basic information

• Product Name: 1-cyclopentyl-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine
• Synonyms: 1-cyclopentyl-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine;1-cyclopentyl-3-iodopyrazolo[3,4-d]pyrimidin-4-amine;1-cyclopentyl-3-iodopyrazolo[3,4-d]pyrimidin-4-amine（WS204208）
• CAS NO: 330794-31-5
• Molecular Formula: C₁₀H₁₂IN₅
• Molecular Weight: 329.14025
• Mol File: 330794-31-5.mol

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 1-cyclopentyl-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-cyclopentyl-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine(330794-31-5)
• EPA Substance Registry System: 1-cyclopentyl-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine(330794-31-5)

Safety Data

• Hazardous Substances Data: 330794-31-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-cyclopentyl-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine is used as a potential therapeutic agent for its antitumor properties, targeting various types of cancer. Its unique structure allows for the modulation of biological pathways involved in tumor growth and progression, offering a promising avenue for the development of new cancer treatments.
Additionally, 1-cyclopentyl-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine is used as a potential antiviral agent, leveraging its ability to interfere with viral replication and infection processes. This makes it a candidate for the development of new antiviral drugs to combat various viral diseases.
Used in Medicinal Chemistry Research:
1-cyclopentyl-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine is used as a building block in the synthesis of novel pharmaceutical agents. Its unique structural features and chemical properties make it a valuable component in the design and development of new drugs with improved efficacy and selectivity.
Furthermore, 1-cyclopentyl-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine is used as a subject of research in drug discovery and design. Its potential biological activities and structural characteristics make it an important target for understanding the relationship between chemical structure and biological function, ultimately contributing to the advancement of medicinal chemistry.

Upstream product

• 137-43-9 Cyclopentyl bromide 
• 151266-23-8 4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidine 
• 1556-18-9 cyclopentyl iodide 

Downstream Products

• 271-63-6 7-Azaindole 
• 1092788-83-4 1-cyclopentyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 1221743-64-1 1-cyclopentyl-3-(4-nitrophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 

Relevant articles and documents

FUSED PYRIMIDINE COMPOUND OR SALT THEREOF

The present invention provides a novel RET inhibitor comprising, as an active ingredient, a compound or a salt thereof that have not been known for their RET inhibitory activity, and also provides an agent for preventing or treating diseases (e.g., malign

NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF

The problem to be solved by the present invention is to provide a novel compound having RET inhibitory activity. The present invention also provides a pharmaceutical preparation that is useful for the prevention and/or treatment of RET-related diseases, p

PYRAZOLOPYRIMIDINE DERIVATIVES AS BTK INHIBITORS FOR THE TREATMENT OF CANCER

This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK). The invention also contemplates the use of t

Benzothiazole Kinase Inhibitors and Methods of Use

The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating lipid kinases such PI3 kinases, tryosine kinases and protein kinases such as mTOR. Also provided in the present invention are methods of using these compositions to modulate these kinases especially for therapeutic applications.

FUSED RING HETEROARYL KINASE INHIBITORS

Provided herein are fused ring heteroaryl compounds useful in a variety of methods, including reducing the activity of certain kinases and treating certain disease states.

Kinase antagonists

The present invention provides novel compounds that are antagonists of PI3 kinase, PI3 kinase and tryosine kinase, PI3Kinase and mTOR, or PI3Kinase, mTOR and tryosine kinase.